1. Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study
- Author
-
Kemp-Casey, Anna, Mintzes, Barbara, Morrow, Richard L., Dormuth, Colin R., Souverein, Patrick C., Roughead, Elizabeth E., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Kemp-Casey, Anna, Mintzes, Barbara, Morrow, Richard L, Dormuth, Colin R, Souverein, Patrick C, and Roughead, Elizabeth E
- Subjects
Male ,Pioglitazone ,adverse drug reaction reporting systems events ,Epidemiology ,Australia ,Interrupted Time Series Analysis ,United Kingdom ,Diabetes Mellitus, Type 2 ,Urinary Bladder Neoplasms ,pharmacovigilance ,diabetes mellitus ,patient safety ,Humans ,Hypoglycemic Agents ,Female ,Thiazolidinediones ,Pharmacology (medical) ,Aged - Abstract
Purpose: National regulators in Australia and the United Kingdom issued safety advisories on the association between pioglitazone use and bladder cancer in July 2011. The Australian advisory noted that males were at higher risk of bladder cancer than females, while the UK advisory highlighted a new recommendation, suggest careful consideration in the elderly due to increasing risk with age. This study examined whether these differences in the advisories had different age- and sex-based impacts in each country. Methods: Interrupted time series analysis was used to compare pioglitazone use (prescriptions/100000 population) in Australia and the United Kingdom for the 24 months before and 11 months after the July 2011 safety advisories (study period July 2009–June 2012). Separate models were used to compare use by sex and age group (≥65 years vs.
- Published
- 2022